教職人員
|
王繼娟
研究領域：藥事經濟學、藥物流行病學、跨類型健康資料整合與分析
本職：副教授
| 最高學歷 | : | Ph.D. in Pharmaceutical Outcomes and Policy, University of North Carolina at Chapel Hill (2007.8-2011.5) |
| 經歷 | : | Associate Professor -School of Pharmacy, National Taiwan University, Taipei, Taiwan Assistant Professor -School of Pharmacy, National Taiwan University, Taipei, Taiwan Post-Doctoral Research Fellow -School of Pharmacy, National Taiwan University, Taipei, Taiwan Philosophy of Doctor in Pharmaceutical Outcomes and Policy (Ph.D.) -University of North Carolina at Chapel Hill, Chapel Hill, NC Master of Health Policy and Administration (M.H.P.A.) -Washington State University, Spokane, WA Bachelor of Science in Pharmacy (B.S.) -National Taiwan University, Taipei, Taiwan |
| 榮譽 | : | 傅爾布萊特學者(2021-2022) 臺大藥學北美校友會 臨床課程教學優良獎(2022. 6) 景康青年教師獎(2020. 12) 臺大藥學北美校友會 特殊貢獻獎(2020. 6) 台美防疫松cohack 優勝團隊(2020. 5) 獲邀至YSF WORLD進行專題講座(2020. 4) http://ysgrant.stpi.narl.org.tw/news_detail.php?no=105 2018 Best Reviewer, Pharmacoepidemiology and Drug Safety(2019. 8) 107年度臺大藥學年度臺大藥學專業學院研究生期刊論文優等獎 (2018.11藥學所碩士班徐鳳儀同學) MOST Young Scholar Fellowship, Ministry of Science and Technology, Taiwan(2018. 5) 2014 Best Reviewer, Pharmacoepidemiology and Drug Safety (2015. 8) 2013 Best Reviewer, Pharmacoepidemiology and Drug Safety (2014. 6) Eahelman Graduate Fellowship: University of North Carolina, UNC Eshelman School of Pharmacy, Chapel Hill, NC (2008.8-2009.7) 教育部補助留學生參加全國性及國際性學術會議或藝能展演(2009.6) Finalist for Postgraduate Best Paper Award, APhA2009 (2009.4) |
| 研究領域 | : | 藥事經濟學、藥物流行病學、跨類型健康資料整合與分析 |
| 研究方向 | : | 1. 藥品上市後的安全性與有效性 2. 成本效益評估、預算衝擊評估 3. 藥品在臨床及市場上使用的現況及其相關的醫療花費 4. 藥品政策評估 5. 全國性問卷資料分析 6. 健康資料整合與AI應用 |
| 老師的話 | : | 如果你對學習新知有熱情、對挑戰創新的題目有興趣，想在目前的基礎上再進修，或是未來想轉換跑道或出國，歡迎你加入我們的實驗室！ |
| 研究室要求 | : | 真誠、熱情、積極、負責 |
| 研究室成員 | : | 1.目前成員： 研究專員：黃鈴雅、林曉杭、顏岑潔 藥學所碩班：楊凱麟、邱韋翔、吳宇涵、黃莉雯 臨藥所博班共同指導(主要指導老師)：陳冠霖(沈麗娟) 2.過去成員： 研究助理：許力霏 藥學所碩班：徐鳳儀、侯伯丞、李幸蓉 臨藥所碩班：黃馨儀、吳采玲、魏筠、廖姮晴、邵祺皓、張祐禎 藥學所碩班共同指導(主要指導老師)：吳欣倫(郭錦樺) 臨藥所碩班共同指導(主要指導老師)：邱賢宗(沈麗娟)、張人予(沈麗娟) 博士後研究員：黃克理 |
Predicting outcomes after hospitalisation for COPD exacerbation using machine learning.
(2025-05) Wu, Chih-Ying ; Hsu, Chien-Ning ; Wang, Charlotte ; JUNG-YIEN CHIEN ; CHI-CHUAN WANG ; FANG-JU LIN
Development and validation of a five-year cardiovascular risk assessment tool for Asian adults aged 75 years and older
(2025-01-08) Hsu, Meng-Chen ; Fu, Yu-Hua ; Wang, Chi-Chuan ; CHAU-CHUNG WU ; Lin, Fang-Ju
Effect of SGLT2 Inhibitors on Diabetes Progression in Statin-Treated Patients: A Population-Based Cohort Study.
(2025) Cheng, Jack Ssu-Chi ; FANG-JU LIN ; Fu, Chih-Min ; Huang, Hsin-Yi ; CHIH-YUAN WANG ; SHIN-YI LIN ; CHI-CHUAN WANG
Association between methylphenidate use and long-term cardiovascular risk in paediatric patients with attention deficit and hyperactivity disorder
(2024-09-03) Liao, Heng-Ching ; Hsu, Chien-Ning ; FANG-JU LIN ; SUSAN SHUR-FEN GAU ; CHI-CHUAN WANG
Enhancing Taiwan's healthcare sustainability: A Delphi study on national medicines policy reforms.
(2024-08-23) CHIH-FEN HUANG ; Chen, Kuan-Lin ; FANG-JU LIN ; CHI-CHUAN WANG ; Gau, Churn-Shiouh ; LI-JIUAN SHEN
(2025-05) Wu, Chih-Ying ; Hsu, Chien-Ning ; Wang, Charlotte ; JUNG-YIEN CHIEN ; CHI-CHUAN WANG ; FANG-JU LIN
Development and validation of a five-year cardiovascular risk assessment tool for Asian adults aged 75 years and older
(2025-01-08) Hsu, Meng-Chen ; Fu, Yu-Hua ; Wang, Chi-Chuan ; CHAU-CHUNG WU ; Lin, Fang-Ju
Effect of SGLT2 Inhibitors on Diabetes Progression in Statin-Treated Patients: A Population-Based Cohort Study.
(2025) Cheng, Jack Ssu-Chi ; FANG-JU LIN ; Fu, Chih-Min ; Huang, Hsin-Yi ; CHIH-YUAN WANG ; SHIN-YI LIN ; CHI-CHUAN WANG
Association between methylphenidate use and long-term cardiovascular risk in paediatric patients with attention deficit and hyperactivity disorder
(2024-09-03) Liao, Heng-Ching ; Hsu, Chien-Ning ; FANG-JU LIN ; SUSAN SHUR-FEN GAU ; CHI-CHUAN WANG
Enhancing Taiwan's healthcare sustainability: A Delphi study on national medicines policy reforms.
(2024-08-23) CHIH-FEN HUANG ; Chen, Kuan-Lin ; FANG-JU LIN ; CHI-CHUAN WANG ; Gau, Churn-Shiouh ; LI-JIUAN SHEN
Bridging the Sentinel System and Artificial Intelligence: Building a Prospective Drug Safety Surveillance System with Claims Data and Electronic Health Records in Taiwan( V )
(2022-03-01～) CHI-CHUAN WANG
Bridging the Sentinel System and Artificial Intelligence: Building a Prospective Drug Safety Surveillance System with Claims Data and Electronic Health Records in Taiwan(4/5)
(2021-03-01～) CHI-CHUAN WANG
The Impact of Sarcopenia on Non- Vi Tamin K Antagonist Oral Anticoagulants Exposure and Clinical Outcomes
(2020-08-01～) SHIN-YI LIN
Bridging the Sentinel System and Artificial Intelligence: Building a Prospective Drug Safety Surveillance System with Claims Data and Electronic Health Records in Taiwan(3/5)
(2020-03-01～) CHI-CHUAN WANG
Bridging the Sentinel System and Artificial Intelligence: Building a Prospective Drug Safety Surveillance System with Claims Data and Electronic Health Records in Taiwan(2/5)
(2019-03-01～) CHI-CHUAN WANG
(2022-03-01～) CHI-CHUAN WANG
Bridging the Sentinel System and Artificial Intelligence: Building a Prospective Drug Safety Surveillance System with Claims Data and Electronic Health Records in Taiwan(4/5)
(2021-03-01～) CHI-CHUAN WANG
The Impact of Sarcopenia on Non- Vi Tamin K Antagonist Oral Anticoagulants Exposure and Clinical Outcomes
(2020-08-01～) SHIN-YI LIN
Bridging the Sentinel System and Artificial Intelligence: Building a Prospective Drug Safety Surveillance System with Claims Data and Electronic Health Records in Taiwan(3/5)
(2020-03-01～) CHI-CHUAN WANG
Bridging the Sentinel System and Artificial Intelligence: Building a Prospective Drug Safety Surveillance System with Claims Data and Electronic Health Records in Taiwan(2/5)
(2019-03-01～) CHI-CHUAN WANG